![Late Complications of High-Dose (≥66 Gy) Thoracic Conformal Radiation Therapy in Combined Modality Trials in Unresectable Stage III Non-small Cell Lung Cancer - Journal of Thoracic Oncology Late Complications of High-Dose (≥66 Gy) Thoracic Conformal Radiation Therapy in Combined Modality Trials in Unresectable Stage III Non-small Cell Lung Cancer - Journal of Thoracic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2040021330/2053563770/gr1.jpg)
Late Complications of High-Dose (≥66 Gy) Thoracic Conformal Radiation Therapy in Combined Modality Trials in Unresectable Stage III Non-small Cell Lung Cancer - Journal of Thoracic Oncology
![Cancer risk from radiation: reduction of dose rate lowers mammary cancer more effectively for adult rats - National Institutes for Quantum Science and Technology Cancer risk from radiation: reduction of dose rate lowers mammary cancer more effectively for adult rats - National Institutes for Quantum Science and Technology](https://www.qst.go.jp/uploaded/image/12721.jpg)
Cancer risk from radiation: reduction of dose rate lowers mammary cancer more effectively for adult rats - National Institutes for Quantum Science and Technology
![Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial - European Urology Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial - European Urology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/5a5bd102-77a0-4ccd-8932-4f7ce042a0ee/gr1_lrg.jpg)
Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial - European Urology
![Distribution in 1-Gy increments of the radiation dose to the kidneys... | Download Scientific Diagram Distribution in 1-Gy increments of the radiation dose to the kidneys... | Download Scientific Diagram](https://www.researchgate.net/publication/302594425/figure/fig4/AS:360305289908224@1462914883139/Distribution-in-1-Gy-increments-of-the-radiation-dose-to-the-kidneys-for-407-patients-and.png)
Distribution in 1-Gy increments of the radiation dose to the kidneys... | Download Scientific Diagram
![Ultra high dose rate (35 Gy/sec) radiation does not spare the normal tissue in cardiac and splenic models of lymphopenia and gastrointestinal syndrome | Scientific Reports Ultra high dose rate (35 Gy/sec) radiation does not spare the normal tissue in cardiac and splenic models of lymphopenia and gastrointestinal syndrome | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-019-53562-y/MediaObjects/41598_2019_53562_Fig1_HTML.png)
Ultra high dose rate (35 Gy/sec) radiation does not spare the normal tissue in cardiac and splenic models of lymphopenia and gastrointestinal syndrome | Scientific Reports
![Phase 3 Multi-Center, Prospective, Randomized Trial Comparing Single-Dose 24 Gy Radiation Therapy to a 3-Fraction SBRT Regimen in the Treatment of Oligometastatic Cancer - International Journal of Radiation Oncology, Biology, Physics Phase 3 Multi-Center, Prospective, Randomized Trial Comparing Single-Dose 24 Gy Radiation Therapy to a 3-Fraction SBRT Regimen in the Treatment of Oligometastatic Cancer - International Journal of Radiation Oncology, Biology, Physics](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/7d23e041-db4b-4b4e-bb5b-7ac432ee0551/gr1_lrg.jpg)
Phase 3 Multi-Center, Prospective, Randomized Trial Comparing Single-Dose 24 Gy Radiation Therapy to a 3-Fraction SBRT Regimen in the Treatment of Oligometastatic Cancer - International Journal of Radiation Oncology, Biology, Physics
![Escalation of radiation dose beyond 30 Gy in 10 fractions for metastatic spinal cord compression - International Journal of Radiation Oncology, Biology, Physics Escalation of radiation dose beyond 30 Gy in 10 fractions for metastatic spinal cord compression - International Journal of Radiation Oncology, Biology, Physics](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2002002259/2007056792/gr1.jpg)
Escalation of radiation dose beyond 30 Gy in 10 fractions for metastatic spinal cord compression - International Journal of Radiation Oncology, Biology, Physics
![Cancers | Free Full-Text | Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels Cancers | Free Full-Text | Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels](https://www.mdpi.com/cancers/cancers-13-02828/article_deploy/html/images/cancers-13-02828-g001.png)
Cancers | Free Full-Text | Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels
![Thoracic radiotherapy at a dose of 60 Gy versus standard regimen for limited stage SCLC increases patient survival - Onco Americas Thoracic radiotherapy at a dose of 60 Gy versus standard regimen for limited stage SCLC increases patient survival - Onco Americas](https://www.oncoamericas.com/wp-content/uploads/2021/05/2_ret_EN.png)
Thoracic radiotherapy at a dose of 60 Gy versus standard regimen for limited stage SCLC increases patient survival - Onco Americas
![Individualized Dose-Escalation of HDR Prostate Brachytherapy Implant to Decrease Required External Beam Radiation Dose: A Retrospective Feasibility Study - Advances in Radiation Oncology Individualized Dose-Escalation of HDR Prostate Brachytherapy Implant to Decrease Required External Beam Radiation Dose: A Retrospective Feasibility Study - Advances in Radiation Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/10b00c5d-3350-4dcf-987d-955ebc07c9d1/gr1_lrg.jpg)